Blood pressure-independent renoprotective effects of small interference RNA targeting liver angiotensinogen in experimental diabetes.
Edwyn O Cruz-LópezLiwei RenEstrellita UijlMarian C Clahsen-van GroningenRichard van VeghelIngrid M GarreldsOliver DomenigMarko PoglitschIvan ZlatevTimothy RooneyAnne KasperPaul NioiDon FosterAlexander H J DanserPublished in: British journal of pharmacology (2022)
Angiotensinogen siRNA exerts renoprotection in diabetic TGR (mRen2)27 rats and this relies, at least in part, on the suppression of renal angiotensin II formation from liver-derived angiotensinogen. Clinical trials should now address whether this is also beneficial in human diabetic kidney disease.
Keyphrases
- angiotensin ii
- type diabetes
- blood pressure
- clinical trial
- angiotensin converting enzyme
- vascular smooth muscle cells
- endothelial cells
- cancer therapy
- wound healing
- cardiovascular disease
- glycemic control
- heart rate
- induced pluripotent stem cells
- hypertensive patients
- pluripotent stem cells
- adipose tissue
- open label
- skeletal muscle
- insulin resistance
- phase ii
- hyaluronic acid